Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other financing activities: 2016-2022

Historic Other financing activities for UroGen Pharma (URGN) over the last 7 years, with Dec 2022 value amounting to $160,000.

  • UroGen Pharma's Other financing activities fell 86.21% to $16,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $177,000, marking a year-over-year decrease of 48.09%. This contributed to the annual value of $160,000 for FY2022, which is 11.11% up from last year.
  • Per UroGen Pharma's latest filing, its Other financing activities stood at $160,000 for FY2022, which was up 11.11% from $144,000 recorded in FY2021.
  • Over the past 5 years, UroGen Pharma's Other financing activities peaked at $215,000 during FY2018, and registered a low of $66,000 during FY2020.
  • In the last 3 years, UroGen Pharma's Other financing activities had a median value of $144,000 in 2021 and averaged $123,333.
  • In the last 5 years, UroGen Pharma's Other financing activities spiked by 411.90% in 2018 and then slumped by 64.65% in 2019.
  • Yearly analysis of 5 years shows UroGen Pharma's Other financing activities stood at $215,000 in 2018, then tumbled by 64.65% to $76,000 in 2019, then declined by 13.16% to $66,000 in 2020, then skyrocketed by 118.18% to $144,000 in 2021, then increased by 11.11% to $160,000 in 2022.